Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer's disease diagnosis in a memory clinic cohort.
Alzheimer’s disease
Biomarkers
Diagnosis
IPMS
Plasma
Simoa
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
18 02 2023
18 02 2023
Historique:
received:
23
11
2022
accepted:
09
02
2023
entrez:
21
2
2023
pubmed:
22
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Alzheimer's disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in clinical practice for early diagnosis. Yet, their cost and perceived invasiveness are a limitation for large-scale implementation. Based on positive amyloid profiles, blood-based biomarkers should allow to detect people at risk for AD and to monitor patients under therapeutics strategies. Thanks to the recent development of innovative proteomic tools, the sensibility and specificity of blood biomarkers have been considerably improved. However, their diagnosis and prognosis relevance for daily clinical practice is still incomplete. The Plasmaboost study included 184 participants from the Montpellier's hospital NeuroCognition Biobank with AD (n = 73), mild cognitive impairments (MCI) (n = 32), subjective cognitive impairments (SCI) (n = 12), other neurodegenerative diseases (NDD) (n = 31), and other neurological disorders (OND) (n = 36). Dosage of β-amyloid biomarkers was performed on plasma samples using immunoprecipitation-mass spectrometry (IPMS) developed by Shimadzu (IPMS-Shim Aβ The amyloid IPMS-Shim composite biomarker (combining APP Our study confirms the potential usefulness of amyloid plasma biomarkers, especially the IPMS-Shim technology, as a screening tool for early AD patients.
Sections du résumé
BACKGROUND
Alzheimer's disease (AD) is a complex neurodegenerative disorder with β-amyloid pathology as a key underlying process. The relevance of cerebrospinal fluid (CSF) and brain imaging biomarkers is validated in clinical practice for early diagnosis. Yet, their cost and perceived invasiveness are a limitation for large-scale implementation. Based on positive amyloid profiles, blood-based biomarkers should allow to detect people at risk for AD and to monitor patients under therapeutics strategies. Thanks to the recent development of innovative proteomic tools, the sensibility and specificity of blood biomarkers have been considerably improved. However, their diagnosis and prognosis relevance for daily clinical practice is still incomplete.
METHODS
The Plasmaboost study included 184 participants from the Montpellier's hospital NeuroCognition Biobank with AD (n = 73), mild cognitive impairments (MCI) (n = 32), subjective cognitive impairments (SCI) (n = 12), other neurodegenerative diseases (NDD) (n = 31), and other neurological disorders (OND) (n = 36). Dosage of β-amyloid biomarkers was performed on plasma samples using immunoprecipitation-mass spectrometry (IPMS) developed by Shimadzu (IPMS-Shim Aβ
RESULTS
The amyloid IPMS-Shim composite biomarker (combining APP
CONCLUSIONS
Our study confirms the potential usefulness of amyloid plasma biomarkers, especially the IPMS-Shim technology, as a screening tool for early AD patients.
Identifiants
pubmed: 36800984
doi: 10.1186/s13195-023-01188-8
pii: 10.1186/s13195-023-01188-8
pmc: PMC9938625
doi:
Substances chimiques
tau Proteins
0
Amyloid beta-Peptides
0
Biomarkers
0
Amyloid
0
Peptide Fragments
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Informations de copyright
© 2023. The Author(s).
Références
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
Neurology. 2022 Feb 15;98(7):e688-e699
pubmed: 34906975
Lancet Neurol. 2020 Nov;19(11):951-962
pubmed: 33098804
Lancet. 2021 Apr 24;397(10284):1577-1590
pubmed: 33667416
Sci Rep. 2021 May 6;11(1):9736
pubmed: 33958661
Dement Geriatr Cogn Disord. 2019;48(3-4):180-195
pubmed: 31991443
Curr Neurol Neurosci Rep. 2014 Nov;14(11):500
pubmed: 25239654
Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(9):353-64
pubmed: 25391320
Alzheimers Dement. 2022 Dec;18(12):2669-2686
pubmed: 35908251
Alzheimers Dement. 2014 Jan;10(1):53-61
pubmed: 23491263
JAMA Neurol. 2019 Sep 01;76(9):1060-1069
pubmed: 31233127
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494
J Alzheimers Dis. 2018;66(3):1235-1244
pubmed: 30412489
J Clin Chem Clin Biochem. 1983 Nov;21(11):709-20
pubmed: 6655447
J Neurosci Methods. 2019 May 1;319:2-6
pubmed: 30352211
J Intern Med. 2021 Sep;290(3):583-601
pubmed: 34021943
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Alzheimers Res Ther. 2015 Jun 01;7(1):30
pubmed: 26034513
JAMA Neurol. 2021 Nov 1;78(11):1375-1382
pubmed: 34542571
Alzheimers Dement. 2015 May;11(5):549-60
pubmed: 25282381
J Immunol Methods. 2012 Apr 30;378(1-2):102-15
pubmed: 22370429
Alzheimers Dement. 2022 Aug;18(8):1484-1497
pubmed: 34845818
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1231-1241
pubmed: 34510001
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Nat Rev Neurol. 2010 Mar;6(3):131-44
pubmed: 20157306
JAMA Netw Open. 2022 Apr 1;5(4):e228392
pubmed: 35446396
Front Aging Neurosci. 2018 May 28;10:138
pubmed: 29892221
Nat Rev Neurol. 2010 Feb;6(2):67-77
pubmed: 20139996
Arch Neurol. 1999 Mar;56(3):303-8
pubmed: 10190820
Nat Commun. 2021 Jun 11;12(1):3555
pubmed: 34117234
Neurol Ther. 2019 Dec;8(Suppl 2):113-127
pubmed: 31833028
Clin Chem. 2020 Feb 1;66(2):282-301
pubmed: 32040572
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
Nat Rev Neurol. 2018 Nov;14(11):639-652
pubmed: 30297701
Sci Rep. 2016 May 31;6:26801
pubmed: 27241045
J Am Geriatr Soc. 2002 Aug;50(8):1431-8
pubmed: 12165002
JAMA Neurol. 2015 Sep;72(9):1029-42
pubmed: 26147946
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
J Alzheimers Dis. 2012;31(1):13-20
pubmed: 22495345
Alzheimers Res Ther. 2019 Apr 22;11(1):34
pubmed: 31010420
Alzheimers Dement. 2017 Aug;13(8):841-849
pubmed: 28734653